Accomplished global commercial leader with deep expertise in retina drug launches Primary architect for the industry-defining launch of EYLEA® while at Regeneron Most recently served as Chief ...

US ophthalmology specialist Ocular Therapeutix announced that David Robinson has agreed to join the company as global chief commercial officer (CCO).

Accomplished global commercial leader with deep expertise in retina drug launches Primary architect for the industry-defining launch of EYLEA- while at Regeneron Most recently served as Chief Marketin ...